Potential conflict of interest: Nothing to report.
Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy†
Version of Record online: 20 FEB 2009
Copyright © 2008 American Neurological Association
Annals of Neurology
Volume 65, Issue 2, pages 209–217, February 2009
How to Cite
Ji, H., Tan, S., Igarashi, J., Li, H., Derrick, M., Martásek, P., Roman, L. J., Vásquez-Vivar, J., Poulos, T. L. and Silverman, R. B. (2009), Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy. Ann Neurol., 65: 209–217. doi: 10.1002/ana.21555
- Issue online: 3 MAR 2009
- Version of Record online: 20 FEB 2009
- Manuscript Accepted: 15 SEP 2008
- Manuscript Revised: 2 SEP 2008
- Manuscript Received: 29 APR 2008
- NIH. Grant Numbers: GM49725, NS43285, NS051402, GM57353, HL067244, NS54017, GM52419
- Robert A. Welch Foundation. Grant Number: AQ1192
- MSMT of the Czech Republic. Grant Numbers: 0021620806, 1M0520
To design a new class of selective neuronal nitric oxide synthase (NOS) inhibitors, and demonstrate that administration in a rabbit model for cerebral palsy (CP) prevents hypoxia-ischemia–induced deaths and reduces the number of newborn kits exhibiting signs of CP.
We used a novel computer-based drug design method called fragment hopping to identify new chemical entities, synthesized them, and conducted in vitro enzyme inhibition studies with the three isozymes of NOS and in vivo experiments to monitor cardiovascular effects on pregnant rabbit dams, NOS activity, and NOx (NO and NO2) concentration in fetal brain, and assess neurobehavioral effects on kits born to saline- and compound treated dams.
The computer-based design led to the development of powerful and highly selective compounds for inhibition of neuronal NOS over the other isozymes. After maternal administration in a rabbit model of CP, these compounds were found to distribute to fetal brain, to be nontoxic, without cardiovascular effects, inhibit fetal brain NOS activity in vivo, reduce NO concentration in fetal brain, and dramatically ameliorate deaths and number of newborn kits exhibiting signs of CP.
This approach may lead to new preventive strategies for CP. Ann Neurol 2008